Compare Bilibili Inc (BILI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bilibili Inc vs Zimmer Biomet Holdings Inc — how do they compare? Bilibili Inc trades at $17.5 (market cap $7.65B), while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.4× Bilibili Inc's market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while Bilibili Inc pays none. Which is the better fit depends on your goals.
| BILI | ZBH | |
|---|---|---|
Market Cap | $7.65B | $18.55B |
Sector | Media | Health |
52-Week High | $35.92 | $107.71 |
52-Week Low | $15.96 | $79.58 |
Enterprise Value | $5.49B | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bilibili (BILI) trades at $17.61, down 7.27% over 24 hours, reflecting bearish technical signals despite strong analyst support. The company reported Q1 2026 EPS of $0.19, beating expectations, with revenue growth projected to $30.8B in 2026. Profit margins improved to 4.58%, though valuation ratios like P/E of 36.24 remain elevated. Recent news highlights a $300 million share repurchase program and upcoming Q2 earnings on August 27, 2026.
The outlook is mixed: bullish fundamentals from earnings beats and buy-side consensus contrast with near-term technical weakness. Key opportunities include user monetization and AI integration, while risks involve competitive pressure and reliance on Chinese market dynamics. The stock's trajectory hinges on Q2 results delivering sustained margin expansion.
Zimmer Biomet (ZBH) trades at $97.9, up 0.12% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology. Key financials show a P/E of 23.6 and net income margin of 9.48%, while cash flow from operations improved to $1.70B in 2025.
The outlook is positive, with a consensus price target of $103.56 offering ~6% upside. Risks include competitive pressures and margin volatility, but consistent earnings beats and institutional accumulation support a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bilibili Inc
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
